San Francisco startup Composition Therapeutics is additionally working on an oral, once-daily GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s anticipations in June whenever a mid-stage study confirmed regular weight loss of about 6% and it designs to begin another mid-stage trial to the tip of the year—that founder and CEO Raymon